Last update Jan. 15, 2023
Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Darifenacin in other languages or writings:
Darifenacin belongs to this group or family:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 15 - 19 | % |
Molecular weight | 427 | daltons |
Protein Binding | 98 | % |
VD | 2.3 | l/Kg |
pKa | 16.2 | - |
Tmax | 6.5 | hours |
T½ | 13 - 19 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an anticholinergic and antispasmotic agent, acetylcholine M3 muscarinic receptor blocker with atropine-like actions, used to treat urinary frequency, urgency, and incontinence and overactive bladder syndrome. Oral administration once a day.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution and high percentage of protein binding), make it unlikely that significant quantities will be transferred to breastmilk.
Its very low oral bioavailability hinders transfer to infant plasma from breastmilk, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
Milk production should be monitored, since anticholinergics can reduce milk production.
Possible anticholinergic symptoms (dry mouth, constipation...) in the infant should be monitored.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.